BioSpace News Archive

Mirum Pharmaceuticals, Inc. announced that data from new analyses showing long-term treatment with LIVMARLI were presented during the European Association for the Study of the Liver Annual Congress, June 5-8, 2024, in Milan, Italy.

MAIA Biotechnology, Inc. today announced Company highlights and key achievements year-to-date, including recent clinical progress for lead candidate THIO, a potential first-in-class cancer telomere targeting agent in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC).

Arbutus Biopharma Corporation announced new preliminary end-of-treatment data from the Phase 2a clinical trial in patients receiving ongoing standard-of-care nucleoside analogue therapy indicating that treatment with imdusiran, Arbutus’ RNAi therapeutic, followed by Barinthus Biotherapeutic’s T-cell stimulating immunotherapeutic, VTP-300, was generally safe, well-tolerated and led to maintenance of lower HBsAg levels during the post-treatment follow-up period in patients with cHBV.

Materna Medical, Inc., a leading innovator in women’s pelvic health solutions, is proud to announce the launch of a new clinical study, Prospective On Market Patient-reported Outcomes for Milli™ Vaginal Dilator (POMPOM).

Leading globally operating CDMO outlines location and design of new manufacturing sites to meet increasing customer demands

4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced positive interim clinical data from the 4D-710 Phase 1/2 AEROW clinical trial for the treatment of cystic fibrosis (CF) lung disease.

Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators, a novel platform of immunotherapies designed to restore innate immune function, and Foundation Medicine, Inc. are pleased to announce a partnership aimed to impact the care of patients with late-stage colorectal cancer undergoing surgery.

Cytek Biosciences, Inc., a leading cell analysis solutions company, announced that its Board of Directors has approved the repurchase of up to an aggregate of $50 million of its common stock, subject to compliance with applicable law.

Amplitude Vascular Systems (AVS), a medical device company focused on safely and effectively treating severely calcified arterial disease, announced today that it has received an investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA) to begin its pivotal trial for pulsatile intravascular lithotripsy (PIVL) therapy.